Pure Biologics (STU:PQB) GF Score: 19/100 (As of Jul. 08, 2026) — 21% Below Median


STU:PQB Pure Biologics SA STU:PQB
19 GF Score
Price €0.40
! 2 Warning Signs
View Full Analysis

What is Pure Biologics GF Score?

Pure Biologics STU:PQB -0.37% 19 GF Score is 19 as of Jul. 08, 2026, which is 21% below its 10-year median of 24.00. GuruFocus rates STU:PQB with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Pure Biologics has the GF Score of 19, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 4/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 2/10
5. Momentum Rank : 3/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Pure Biologics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Pure Biologics  (STU:PQB) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Pure Biologics GF Score Related Terms

STU:PQB vs VRTX, REGN, ALNY: GF Score Comparison

For the Biotechnology subindustry, Pure Biologics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pure Biologics GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pure Biologics's GF Score distribution charts can be found below:

* The bar in red indicates where Pure Biologics's GF Score falls into.


STU:PQB
19GF Score
Pure Biologics SA STU:PQB
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 19 mean?
Pure Biologics (STU:PQB) has a GF Score of 19 as of Jul. 08, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Pure Biologics and its competitors. This is 21% below median its historical median of 24.00. Over the past decade, Pure Biologics' GF Score has ranged from 4.00 to 53.00.
Is Pure Biologics' GF Score too high?
Pure Biologics' current GF Score of 19 is 21% below median its 10-year median of 24.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 53.00. Overall, Pure Biologics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pure Biologics' GF Score compare to VRTX and REGN?
Pure Biologics' GF Score of 19 can be compared against companies in the Biotechnology industry. Historically, Pure Biologics' own GF Score has ranged from 4.00 to 53.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Pure Biologics and its competitors. Pure Biologics's current GF Score is 19, which is 21% below median its own 10-year median of 24.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pure Biologics stock overvalued right now?
Pure Biologics (STU:PQB) has a current GF Score of 19. The current GF Score is 19, which is 21% below median its 10-year median of 24.00. Pure Biologics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Pure Biologics (STU:PQB), the current GF Score is 19 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pure Biologics Business Description

Other Exchanges PUR:Poland
Address ul. Dunska 11, Wroclaw, POL, 54-427
Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.
19GF Score

Get the complete analysis for STU:PQB

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.40
Price